Oliver Dorigo, MD
Gynecologic Oncology · Stanford, CANPI 1306873294
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Tesaro, Inc. at 46.8% of the total. Reporting peaked in 2019 at $48,571 and has fallen 96.5% since, to $1,684 in 2025. Among gynecologic oncology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 99 payments — averaging $853.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tesaro, Inc.$40K
- AstraZeneca$15K
- Immunogen, Inc.$9K
- GSK$5K
- Merck$4K
- Intuitive Surgical$3K
- plus $9K from 8 others
Across 192 payments — averaging $3637.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- EMD Serono, Inc.$265K
- Novartis$150K
- AstraZeneca$75K
- Takeda Pharmaceuticals U.S.A., Inc.$68K
- Genentech, Inc.$62K
- Clovis Oncology, Inc.$51K
- plus $27K from 2 others
What the payments were for
- Consulting fees$46,15355%
- Speaking & faculty fees$25,91831%
- Travel & lodging$7,4029%
- Food & beverage$2,5553%
- Education$2,5003%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tesaro, Inc. | 44 | $39,595 |
| AstraZeneca | 14 | $15,341 |
| Immunogen, Inc. | 9 | $9,204 |
| GSK | 6 | $5,438 |
| Merck | 3 | $3,500 |
| Intuitive Surgical | 3 | $2,565 |
| Clovis Oncology, Inc. | 3 | $2,101 |
| Eisai Inc. | 1 | $1,875 |
| Blueprint Medicines Corporation | 1 | $1,680 |
| Genentech USA, Inc. | 1 | $1,330 |
| Eli Lilly | 2 | $1,053 |
| AbbVie | 6 | $617 |
| Medtronic | 4 | $183 |
| Myriad Genetic Laboratories, Inc. | 2 | $45 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$84,528 in reported general payments places this provider in the 90th percentile of 152 gynecologic oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gynecologic oncology in Stanford
- Amer KaramStanford$168K
- Jonathan BerekStanford$54K
- Babak LitkouhiStanford$4K
- John ChanSan Francisco$2M
- Dana ChaseLos Angeles$1.3M
- Ramez EskanderEncinitas$706K
- Krishnansu TewariOrange$495K
- Fabio CappucciniOrange$313K
- Mehdi Moslemi-KebriaUpland$225K
- Rebecca BrooksSacramento$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.